Arca
Skip to content
Tools
Tools

DNA polymerase (alpha/delta/epsilon)

Family in Homo sapiens that 6 drugs act on.

  • Drugs that act on it: 6
  • Approved: 4
  • In phases 1 to 3: 2
  • Sponsors: 5
  • Genes: 11

Who is on it, and how far along

Every drug ChEMBL records acting on POLA1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 6

Approved4

  • Gemcitabine
  • Fludarabine phosphate
  • Cytarabine
  • Clofarabine

Phase 30

    Phase 22

    • Troxacitabine
    • Aspacytarabine

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: DNA polymerase (alpha/delta/epsilon) inhibitor.
      GemcitabineApprovedEli LillySmall moleculeInhibitor1,014
      Fludarabine phosphateApprovedSanofiSmall moleculeInhibitor915
      CytarabineBoxed warningApprovedTeva Pharmaceutical IndustriesSmall moleculeInhibitor419
      ClofarabineApprovedSanofiSmall moleculeInhibitor19
      TroxacitabinePhase 2Takeda Pharmaceuticals USASmall moleculeInhibitor1
      AspacytarabinePhase 2BioSight Ltd.Small moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 33 in all, from ClinicalTrials.gov.
      Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML)CytarabinePhase 3Not yet recruitingUniversity Hospital, ToulouseNov 19, 2026
      A Phase 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subjects With R/R AMLCytarabinePhase 2Not yet recruitingDana-Farber Cancer InstituteNov 19, 2026
      A Post-Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chinese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML)CytarabinePhase 4Not yet recruitingDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyNov 19, 2026
      First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That Have Returned or Not Responded to TreatmentFludarabine phosphatePhase 1RecruitingCellogen Therapeutics Pvt. Ltd.Nov 19, 2026
      Determining the Safety of CAR T-Cell Therapy for LymphomaFludarabine phosphatePhase 1Not yet recruitingUniversity of ChicagoNov 19, 2026
      A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic CancerGemcitabinePhase 1 / Phase 2Not yet recruitingTianjin Medical University Cancer Institute and HospitalNov 18, 2026
      T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies.Fludarabine phosphatePhase 1Not yet recruitingSt. Jude Children's Research HospitalNov 17, 2026
      Iparomlimab and Tuvonralimab Injection (QL1706)Combined With Chemotherapy (AG) and SBRT as First-Line Treatment for Locally Advanced Pancreatic CancerGemcitabinePhase 2Active, not recruitingTongji HospitalNov 16, 2026
      Effects of Hypoxia or Caffeine on 4km Time-trial Morning Cycling.CytarabinePhase 4RecruitingLiverpool John Moores UniversityNov 13, 2026
      Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell LymphomaFludarabine phosphatePhase 1 / Phase 2Not yet recruitingUniversity of Michigan Rogel Cancer CenterNov 12, 2026
      BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple MyelomaFludarabine phosphatePhase 1Not yet recruitingLiping DouNov 10, 2026
      A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic CancerGemcitabineNot applicableNot yet recruitingRuijin HospitalNov 10, 2026
      An Exploratory Study of the Efficacy and Safety of SBRT Following Induction Therapy With Neoadjuvant Immunotherapy Combined With Chemotherapy in Muscle-Invasive Bladder CancerGemcitabineNot applicableNot yet recruitingTianjin Medical University Cancer Institute and HospitalNov 10, 2026
      Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney CancerFludarabine phosphatePhase 2Not yet recruitingBeth Israel Deaconess Medical CenterNov 9, 2026
      A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal CarcinomaGemcitabinePhase 3RecruitingCSPC Megalith Biopharmaceutical Co.,Ltd.Nov 9, 2026
      Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute LeukemiaFludarabine phosphatePhase 2Enrolling by invitationGuangdong Second Provincial General HospitalNov 6, 2026
      Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaCytarabinePhase 1Not yet recruitingCity of Hope Medical CenterNov 3, 2026
      Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder CancerGemcitabinePhase 3Not yet recruitingAssiut UniversityNov 3, 2026
      Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerGemcitabinePhase 2RecruitingFox Chase Cancer CenterNov 2, 2026
      MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC )CytarabineNot applicableNot yet recruitingFirst Affiliated Hospital of Zhejiang UniversityOct 29, 2026
      To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaFludarabine phosphatePhase 3Not yet recruitingKite, A Gilead CompanyOct 29, 2026
      Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal CarcinomaGemcitabinePhase 2Not yet recruitingSun Yat-sen UniversityOct 29, 2026
      Low Dose Induction for Pediatric Acute Myeloid Leukemia PatientsCytarabineNot applicableRecruitingAzza Shibl SayedOct 9, 2026
      Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)CytarabinePhase 2Not yet recruitingNational Cancer Institute (NCI)Oct 7, 2026
      Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete RemissionClofarabineNot applicableNot yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaJun 12, 2026
      Cord Blood Transplantation in Children and Young Adults With Blood CancerClofarabinePhase 2RecruitingMemorial Sloan Kettering Cancer CenterMay 5, 2026
      Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line ImmunotherapyTroxacitabinePhase 2RecruitingCHA UniversityMar 25, 2026
      Vyxeos® With Clofarabine for Pediatric AMLClofarabinePhase 1RecruitingPrincess Maxima Center for Pediatric OncologySep 5, 2025
      Clofarabine Therapy in Locally Advanced or Metastatic Urothelial CarcinomaClofarabinePhase 1 / Phase 2RecruitingEkaterina LaukhtinaJun 24, 2025
      Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in ChildrenClofarabinePhase 2RecruitingWest China Second University HospitalJun 15, 2025
      Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn DiseaseClofarabinePhase 1 / Phase 2Not yet recruitingStanford UniversityMay 23, 2025
      Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft TransplantationClofarabinePhase 2RecruitingNantes University HospitalFeb 12, 2024
      Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCTClofarabinePhase 2RecruitingNantes University HospitalJun 23, 2023

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2363042, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.